# 007_1 | all_patients

## Case

# Case vignette: 62-year-old woman with second primary breast cancer

Clinical summary (chronologic, oncology-focused):

- Demographics and relevant history:
  - Age/sex: 62-year-old woman, postmenopausal (menopause at 47 years).
  - Reproductive history: Nulliparous; menarche at 13.
  - Medical history: Hyperlipidemia, hypothyroidism, prior left ovarian cyst excision (remote), prior vulvar carcinoma in situ treated 10 years earlier (and recurrence 4 months before current evaluation treated with topical imiquimod). Ongoing daily alcohol use and >30 pack-year cigarette smoking history.
  - Medications: Atorvastatin, levothyroxine, alendronate, calcium carbonate, bupropion.
  - Family history: Mother died of colon cancer at 54; paternal aunt had breast cancer at 90; no strong family history of breast/ovarian cancer reported.

- First breast cancer (left breast), 6 years prior to current presentation:
  - Detection: routine mammogram showing calcifications.
  - Pathology: stereotactic core → excisional biopsy demonstrated grade 1 invasive ductal carcinoma (0.7 cm) with associated intermediate-grade DCIS; ER-positive, PR-positive, HER2-negative by IHC.
  - Surgical management: wide excision (no residual carcinoma on re-excision) and sentinel-lymph-node biopsy (negative).
  - Local therapy: adjuvant whole-breast radiation 50 Gy + 10 Gy boost completed 3 months after wide excision.
  - Systemic therapy: patient declined adjuvant tamoxifen.

- Interval surveillance and findings:
  - Over following 3 years: multiple mammograms with calcifications in contralateral (right) breast; biopsies showed fibrocystic change with atypia.
  - 5.5 years after initial cancer: new mild left-breast nodularity; mammography negative.
  - 3 months later: persistent left-breast nodularity prompted bilateral breast MRI (gadolinium), which identified an enhancing mass in the central inferior right breast measuring 1.8 x 1.1 cm; subsequent mammogram confirmed a vague corresponding density; MRI-guided core biopsy performed.

- Second breast cancer (right breast), index lesion:
  - Presentation: clinically palpable/ MRI-detected enhancing mass; core biopsy revealed invasive ductal carcinoma.
  - Pathology on definitive surgery (right partial mastectomy with needle localization + sentinel-node biopsy):
    - Histology/grade: grade 3 invasive ductal carcinoma (1.0 x 0.7 cm) with adjacent grade 3 DCIS.
    - Lymphovascular invasion: absent.
    - Margins: negative.
    - Nodal status: sentinel-lymph-node biopsy (3 SLNs) negative for metastasis → pT1b, pN0.
    - Receptor profile: ER-positive, weak PR expression, HER2 3+ by IHC.
    - HER2 gene status: FISH amplification with HER2:CEP17 ratio 6.6 (signal count performed on 60 tumor cells as reported).

- Laboratory and baseline functional status:
  - Baseline labs (CBC, LFTs, renal function, electrolytes, albumin) were reported as normal.
  - Functional status: patient appeared well on exam, vitals within normal limits; performance-status-equivalent: ECOG 0–1.

- Multidisciplinary assessment and risk estimate:
  - Pathologic stage: node-negative, small (≤1 cm) invasive ductal carcinoma; high histologic grade (grade 3); HER2 amplified; ER-positive.
  - Estimated 10-year risk of recurrence without systemic therapy approximated at ~15% by the treating team (Adjuvant! Online referenced); higher relative risk given HER2 overexpression and high grade but small absolute risk given size and node-negative status.

- Treatment decisions recorded in case:
  - The team recommended four cycles of doxorubicin plus cyclophosphamide (AC), followed by 1 year of trastuzumab, plus adjuvant endocrine therapy with an aromatase inhibitor for postmenopausal, ER-positive disease. Trastuzumab was to be given after AC because of cardiac toxicity concerns with concurrent anthracycline and trastuzumab.

- Molecular/genomic data available from case report:
  - HER2: strong (3+) IHC; FISH amplification ratio 6.6 (count based on 60 tumor cells). No next-generation sequencing data, no somatic mutation VAF/read depth reported, and no tumor mutational burden (TMB) or MSI data reported in the original case.
  - Biomarkers: ER-positive (strong), PR weakly positive, HER2 amplified by FISH; no PD-L1, FISH for other genes, or other molecular panels were reported.

- Key clinical issues raised by the case (for advanced assessment):
  - Distinction between contralateral new primary vs metastasis (histologic differences, presence of DCIS favor second primary).
  - Applicability of adjuvant trastuzumab for pT1bN0 HER2+ disease and regimen selection (anthracycline-based ± trastuzumab vs non-anthracycline paclitaxel–trastuzumab [APT regimen]).
  - Cardiac-risk assessment and monitoring strategy for trastuzumab after prior anthracycline exposure.
  - Benefit magnitude of chemotherapy and trastuzumab given small tumor size and node-negative status; weighing absolute benefit vs toxicity given age and comorbidities.

References:
- Case record: N Engl J Med 2007;357:1640-8 (Case 32-2007).
- Tolaney SM et al., Adjuvant Paclitaxel and Trastuzumab for Node‑Negative, HER2‑Positive Breast Cancer (APT), N Engl J Med 2015. https://www.nejm.org/doi/full/10.1056/NEJMoa1406281
- APT long-term/10-year analysis (Lancet Oncology 2023). https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00051-7/abstract
- Review on small node‑negative HER2+ cancers. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9156575/
- NCCN Breast Cancer Guidelines (adjuvant HER2 therapy recommendations). https://jnccn.org/view/journals/jnccn/22/5/article-p331.xml
- NSABP B-31 / NCCTG N9831 cardiac outcomes (Romond et al.). https://pubmed.ncbi.nlm.nih.gov/22987084/
- ESMO consensus on management of cardiac disease in oncology patients. https://www.esmo.org/guidelines/esmo-consensus-recommendations-management-of-cardiac-disease



---

## Q1 (007_1)

For this 62-year-old woman with a 1.0 × 0.7 cm, grade 3, ER-positive, HER2 3+/FISH-amplified (HER2:CEP17 ratio 6.6) node-negative breast cancer, what adjuvant systemic therapy regimen would be considered optimal today to maximize invasive-disease-free survival while balancing cardiac risk, and what patient-specific factors should guide the choice between an anthracycline-based approach and a non-anthracycline approach?

### Answer 1

Guideline consensus and contemporary evidence support offering HER2-targeted adjuvant therapy for pT1bN0 HER2-amplified tumors. Two reasonable options are: (1) a non-anthracycline regimen — paclitaxel plus trastuzumab (APT regimen) — appropriate for small node-negative HER2+ tumors with excellent invasive-disease-free survival and low cardiac toxicity; or (2) an anthracycline-containing regimen (e.g., AC → taxane with trastuzumab given sequentially) for patients considered higher risk. Choice should consider tumor biology (high grade increases potential absolute benefit), patient age, baseline LVEF, cardiovascular comorbidities (smoking, hypertension, coronary disease), prior therapies, and the small absolute benefit given tumor size. For this patient (age 62, normal baseline labs, no cardiac disease reported), APT is a guideline‑supported, lower-cardiotoxicity option; anthracycline→trastuzumab is reasonable if patient accepts higher cardiac risk for possibly incremental benefit.

---

## Q2 (007_2)

Given the patient’s desire for an aggressive approach but concern about cardiac toxicity from trastuzumab after anthracyclines, what non‑anthracycline adjuvant regimens are evidence‑supported for her tumor type, and what is the expected cardiotoxicity profile of those regimens compared with anthracycline+trastuzumab?

### Answer 2

Evidence-supported non-anthracycline regimens include paclitaxel+trastuzumab (APT) for small node-negative HER2+ tumors and TCH (docetaxel+carboplatin+trastuzumab). APT demonstrates excellent outcomes with very low rates of symptomatic heart failure. TCH has lower cardiac toxicity than anthracycline+trastuzumab (BCIRG-006 comparisons) but higher hematologic toxicity. Anthracycline+trastuzumab regimens show a higher incidence of clinically significant heart failure (~3–4% in large randomized trials) compared with substantially lower rates with APT/TCH.

---

## Q3 (007_3)

Is trastuzumab monotherapy (adjuvant trastuzumab without any cytotoxic chemotherapy) an evidence‑based standard option for a patient with pT1bN0 HER2‑amplified disease such as this case, and under what circumstances (if any) might trastuzumab alone be considered?

### Answer 3

Trastuzumab monotherapy has not been established as a standard adjuvant option in randomized trials; the APT trial combined paclitaxel with trastuzumab and demonstrated efficacy in small tumors. Guidelines endorse trastuzumab together with a chemotherapy backbone, individualized to risk and cardiac considerations. Trastuzumab alone may only be considered in exceptional circumstances (clinical trial or contraindication to all chemotherapy) after informed discussion regarding limited evidence.

---

## Q4 (007_4)

For this patient who will receive trastuzumab after an anthracycline-containing regimen (as recorded in the case), what is the recommended cardiac surveillance schedule by guideline consensus during and after trastuzumab, and how should asymptomatic declines in left ventricular ejection fraction (LVEF) be managed?

### Answer 4

Baseline LVEF assessment is required before trastuzumab. Guideline-consensus monitoring typically repeats LVEF every ~3 months during trastuzumab therapy (or per institutional protocol), and additional checks if symptoms develop. An asymptomatic absolute LVEF decline of ≥10 percentage points to below the lower limit of normal (or per trial-specific thresholds) should prompt trastuzumab interruption, cardiology evaluation, and initiation of guideline-directed medical therapy (ACE inhibitor/ARB, beta-blocker). Trastuzumab can be resumed if LVEF recovers to acceptable limits after treatment and reassessment.

---

## Q5 (007_5)

Summarize the evidence base for choosing an aromatase inhibitor over tamoxifen in postmenopausal women and whether HER2 amplification modifies the expected benefit of endocrine therapy for this patient.

### Answer 5

Randomized trials (BIG 1-98, ATAC) demonstrated that aromatase inhibitors (AIs) improve disease-free survival compared with tamoxifen in postmenopausal women with HR+ early breast cancer. Guidelines recommend inclusion of an AI in the adjuvant endocrine strategy for postmenopausal women. Some retrospective data suggest tamoxifen benefit may be attenuated in HER2+ tumors, but endocrine therapy still reduces recurrence risk in ER+ HER2+ disease. For this patient (postmenopausal, ER+), an AI is the preferred endocrine agent.

---

## Q6 (007_6)

Should a multigene recurrence score (e.g., Oncotype DX) or other genomic assay be used to decide on adjuvant chemotherapy or to de-escalate HER2-directed therapy in this HER2-amplified tumor, and what are the limitations of genomic assays in HER2-positive disease?

### Answer 6

Multigene recurrence assays such as Oncotype DX were validated in HER2-negative, ER-positive populations; they are not validated to guide therapy in HER2-amplified tumors and should not be used to omit trastuzumab. Genomic assays have limited utility for deciding HER2-directed therapy in HER2+ disease. Clinical-pathologic factors and HER2-specific evidence should guide treatment.

---

## Q7 (007_7)

If this patient later develops distant metastatic recurrence after receipt of trastuzumab-based adjuvant therapy, what would be the contemporary first-line systemic therapy options for HER2-positive metastatic disease, and how does prior adjuvant exposure to trastuzumab influence choice?

### Answer 7

First-line therapy for HER2+ metastatic breast cancer typically includes dual HER2 blockade with pertuzumab + trastuzumab plus a taxane (CLEOPATRA regimen) and remains standard irrespective of prior adjuvant trastuzumab exposure. Prior adjuvant trastuzumab does not generally preclude use of CLEOPATRA in the metastatic setting. For subsequent lines after progression on trastuzumab-based therapy, trastuzumab-deruxtecan (T-DXd) has shown superior efficacy to T-DM1 and is an important option. Clinical trials are encouraged for further sequencing strategy.

---

## Q8 (007_8)

How does the presence of adjacent grade-3 DCIS with the invasive carcinoma support the interpretation of this tumor as a new primary in the contralateral breast rather than a metastasis from the prior left breast cancer, and how would this distinction alter adjuvant management?

### Answer 8

Adjacent DCIS strongly favors a new primary tumor because DCIS is a precursor lesion present in primary breast cancers but not in hematogenous metastases. Histologic and biomarker discordance between the left (low-grade, HER2-negative) and right (high-grade, HER2-amplified) tumors further support independent primaries. If this were a metastatic lesion, treatment would be palliative systemic therapy and local therapy would be individualized; because this is a new primary, curative-intent local therapy and adjuvant systemic therapy are appropriate.

---

## Q9 (007_9)

What are the considerations for delivering adjuvant radiation therapy to the contralateral breast after prior ipsilateral breast irradiation, and is repeat breast-conserving therapy with radiation feasible in this clinical context?

### Answer 9

Repeat breast conservation with radiation to the contralateral breast is feasible when radiation fields do not overlap and modern planning can limit scatter; in this case the initial left-field ended near the midline and the tumor location permitted non-overlapping right-breast fields. Careful planning, dosimetry records, and minimizing scatter are required. Prior radiation modestly increases contralateral breast-cancer risk, and cumulative doses and potential normal-tissue effects must be considered.

---

## Q10 (007_10)

Suppose tumor sequencing on recurrence reveals a PIK3CA hotspot mutation present at a variant allele fraction (VAF) of 12% with a read depth of 500 reads for that locus. In the context of HER2-amplified, ER-positive disease, how would the presence of a PIK3CA mutation influence therapeutic decisions and what is the clinical significance of the reported VAF/read depth in this scenario?

### Answer 10

PIK3CA mutations are common and may be associated with relative resistance to certain HER2 therapies in preclinical/retrospective data, but they do not eliminate the role of HER2-targeted agents. In HR+ HER2-negative disease, PIK3CA is actionable with alpelisib plus endocrine therapy; in HER2+ disease, PI3K inhibitors are not standard and should generally be considered in clinical trials or specialized contexts. A VAF of 12% at 500x depth indicates a reliably detected subclonal variant (high technical confidence) and suggests intratumoral heterogeneity; this may inform trial selection or strategy for overcoming resistance but would not by itself mandate off-label PI3K inhibitor use in HER2+ disease.

---
